Copyright
©The Author(s) 2023.
World J Cardiol. Feb 26, 2023; 15(2): 64-75
Published online Feb 26, 2023. doi: 10.4330/wjc.v15.i2.64
Published online Feb 26, 2023. doi: 10.4330/wjc.v15.i2.64
Table 1 Main demographics of patients treated with either balloon angioplasty or stenting included in meta-analysis
Ref. | Patients | Mean age (yr) | Males (%) | Frequency of clinical symptoms; Dyspnea (%) | Hemoptysis (%) | Asymptomatic (%) | Severe PVS treated (n) |
Qureshi et al[19] | 19 | 51 ± 13 | NA | 95 | 63 | 5 | 37 |
Prieto et al[7] | 44 | 53 ± 11 | 70 | 88 | 23 | 7 | 68 |
Neumann et al[6] | 12 | 58 | 70 | 77 | 8 | 17 | 15 |
Fender et al[20] | 113 | 50 | 77 | 67 | 27 | 0 | 178 |
Cory et al[5] | 30 | Median age-6.4 m | 50 | NA | NA | NA | 58 |
Schoene et al[15] | 39 | 62.1 ± 9.0 | 60 | 79 | 26 | NA | 61 |
Kurita et al[9] | 31 | 7 mo | 65 | NA | NA | NA | 53 |
Suntharos et al[8] | 199 | 55 ± 12 | 78 | 83 | 13 | 13 | 319 |
Table 2 Clinical characteristics of patients treated with either balloon angioplasty or stenting included in meta-analysis
Ref. | Study type | Enrolment Period | Main inclusion criteria | Imaging after ablation | Mean time between PVI and clinical symptoms | Revascularization approach | Stent size | Acute angiographic success | Primary outcome at follow-up | Follow-up |
Qureshi et al[19], 2003 | Observational retrospective study | 2000-2002 | Severe PVS with clinical symptoms | CT-scans in symptomatic patients | 4 mo | Stepwise | 4-10 mm | NA | Freedom of reintervention | 10 ± 9 mo |
Prieto et al[7], 2008 | Observational retrospective study | 2000-2007 | Severe PVS with clinical symptoms | CT-scans, lung perfusion scans in symptomatic patients | 11.5 mo | Stepwise/primary stenting | 8-10 mm | Residual stenosis ≤ 30% | Recurrence of symptoms requiring reintervention | 25 ± 21 mo |
Neumann et al[6], 2009 | Observational prospective study | 2003-2005 | Severe PVS (> 70%) with clinical symptoms and/or significant perfusion defect | Surveillance imaging with MRI, lung perfusion scans, CT scans, TTE every 3 mo | NA | Stepwise (if rebound stenosis was observed after balloon dilatation)/primary stenting | 8-12 mm | NA | Clinically symptomatic restenosis | 48 mo |
Fender et al[20], 2016 | Observational prospective study | 2000-2014 | Severe PVS (> 75%) with clinical symptoms | Surveillance imaging with CT-scans at 3 mo + CT-scans and lung perfusion scans in symptomatic patients | 4.0 ± 3.0 mo | Stepwise | 6-10 mm + DES 4 mm | Residual stenosis < 20% | Clinically symptomatic restenosis | 48 mo |
Cory et al[5], 2017 | Observational retrospective study | 2005-2016 | Catheter intervention for PVS for patients < 18 yr | NA | NA | Stepwise/primary stenting | Median-DES 4 mm, BMS 5 mm | NA | Mortality following transcatheter PV intervention | Median of 30.6 mo |
Schoene et al[15], 2018 | Observational retrospective study | 2004-2017 | Symptomatic PVS with > 70% in a single stenosis or > 60% in multiple ipsilateral stenosis | Initial screening process from 2004-2007- TEE 6-12 mo after PVI or when symptomatic, subsequent CT or MRI. Screening terminated in 2008, symptomatic patients underwent CT, MRI and/or PV angiography | 10.2 ± 8.0 mo | Stepwise/primary stenting | Median stent- 7 mm × 20 mm, DES 5 mm | Residual stenosis < 10%-20% | Restenosis rate following transcatheter intervention | Median of 6 mo |
Kurita et al[9], 2019 | Observational retrospective study | 2001-2017 | PVS associated with total anomalous pulmonary venous connection and isolated congenital PVS | Combination of ultrasound, CT and angiography | Median 7 from birth | Stepwise/primary stenting-PCI/hybrid surgery | 3-8 mm | NA | In-stent restenosis following stent placement using CT or angiography ≥ 50% higher stenosis of stent size | 19 mo |
Suntharos et al[8], 2019 | Observational retrospective study | 2000-2016 | PVS after PVI undergoing PCI | CT-scan pulmonary vein protocol, quantitative lung perfusion scan | NA | Stepwise/primary stenting | 3-16 mm | NA | Freedom of reinrevention | Median follow up-17 mo |
Table 3 Follow up characteristics after revascularization
Ref. | Antiplatelet therapy | Imaging modalities | Restenosis definition |
Qureshi et al[19], 2003 | NR | CT-scans every 3 mo | PV narrowing > 70% of the original PV lumina |
Prieto et al[7], 2008 | NR | CT-scans, lung perfusion scans at 3-12-24 mo | NR |
Neumann et al[8], 2009 | ASA+Clopidogrel+Coumadin for 3 mo | CT-scans, lung perfusion scans every 3 mo | PV narrowing > 70%of the original PV lumina before PVI |
Fender et al[20], 2016 | Coumadin+Clopidogrel | CT-scans, lung perfusion scans at 3-12-24 mo | PV narrowing > 75% in the previously treated PV |
Cory et al[5], 2017 | NA | Angiography | Vein loss defined as PV atresia or PVs of uncertain status in deceased patients |
Schoene et al[15], 2018 | ASA 4 weeks+Clopidogrel 6 mo+Coumadin or DOACs | CT-scans, MR imaging | PV narrowing > 70% in the previously treated PV |
Kurita et al[9], 2019 | ASA, Ticlopidin, Warfarin | CT or angiography | In stent restenosis: ≥ 50% luminal narrowing |
Suntharos et al[8], 2019 | Anticoagulation followed by low-dose aspirin | CT-scans, lung perfusion scans, angiography based on intervention-3 mo, 6 mo, 1yr | Severe restenosis/concern for progression to total occlusion |
Table 4 Summary of evidence
Outcomes | Anticipated absolute effectsa (95%CI) | Relative effect (95%CI) | No. of participants (studies) | Certainty of the evidence (GRADE)b | |
Risk with PSI | Risk with PBA | ||||
Restenosis | 251 per 1000 | 493 per 1000 (278 to 711) | OR 2.91 (1.15 to 7.37) | 487 (8 observational studies) | ⊕⊕⊕◯ MODERATEc |
Procedure related complications | 87 per 1000 | 82 per 1000 (21 to 264) | OR 0.94 (0.23 to 3.76) | 191 (3 observational studies) | ⊕⊕⊕◯ MODERATEc |
- Citation: Agasthi P, Sridhara S, Rattanawong P, Venepally N, Chao CJ, Ashraf H, Pujari SH, Allam M, Almader-Douglas D, Alla Y, Kumar A, Mookadam F, Packer DL, Holmes DR Jr, Hagler DJ, Fortuin FD, Arsanjani R. Safety and efficacy of balloon angioplasty compared to stent-based-strategies with pulmonary vein stenosis: A systematic review and meta-analysis. World J Cardiol 2023; 15(2): 64-75
- URL: https://www.wjgnet.com/1949-8462/full/v15/i2/64.htm
- DOI: https://dx.doi.org/10.4330/wjc.v15.i2.64